Treatment
YKST02 clinical trials
We’re tracking 2 recruiting studies that include YKST02, each written for real people, not researchers, below.
Recruiting studies
- NCT06574568RecruitingPhase 1
Study of YKST02 for relapsed or refractory multiple myeloma
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07498673RecruitingEarly Phase 1
Testing YKST02 for IgA nephropathy
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
Wuhan, HubeiAges 18–75
What YKST02 is being studied for
Conditions with recruiting YKST02 studies.
Common questions
- Are there clinical trials studying YKST02?
- Yes. Clin2 currently lists 2 recruiting studies that include YKST02, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a YKST02 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is YKST02 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether YKST02 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.